2021
   Online, In the cloud

I-01 Ana Alarcia Lacalle Population pharmacokinetic modelling of levetiracetm in criticaclly ill patients. Influence of creatinine clearance on the probability to attain target concentrations.

I-02 Michael Cloesmeijer Capped dosing of desmopressin in Von Willebrand disease: Quantification of the relationship between desmopressin plasma concentration and Von Willebrand factor activity

I-03 Alix Démaris Simulation based assessment of different dosing strategies for anti-TNFα monoclonal antibodies in Crohn’s disease patients

I-04 Thomas Dumortier A model-based approach to support a label update for flexible dosing of secukinumab in patients with plaque psoriasis

I-05 Omar Elkayal Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and exposure in term neonates

I-06 Ruben Faelens Building model-informed precision dosing software using R: blueprint for a state-of-the-art development process

I-07 Wannee kantasiripitak A multi-model averaging approach improves the performance of model-guided infliximab de-escalation in patients with inflammatory bowel diseases

I-08 Simon Koele Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients

I-09 Matthias König A physiologically based computational model of indocyanine green liver function tests predicts survival in hepatectomy

I-10 Enrica Mezzalana Population pharmacokinetic modelling and simulation of imeglimin in type 2 diabetes patients to support dose recommendations to patients with renal impairment

I-11 Robin Michelet Using microdose-based activity measurement to individualise dosing of cytochrome P450 metabolised drugs: a case study with yohimbine and tamoxifen

I-12 Sami Ullah Population pharmacokinetics suggests that an intraperitoneal daily dose of 750 mg meropenem is sufficient to treat peritonitis in patients undergoing automated peritoneal dialysis

I-14 Niklas Hartung Nonparametric goodness-of-fit testing for parametric covariate models

I-15 Sara Carolina Henriques Population pharmacokinetic analysis on data from a bioequivalence study – Effects of hormonal contraceptives on drug exposure

I-16 Galina Kolesova Virtual Patient Populations: Comparison of Approaches in Application to QSP Model Of Erythropoiesis

I-17 Venelin Mitov A unifying approach to sampling NLME model parameters

I-18 Giovanni Smania Conditional distribution modeling for covariates simulation using classification and regression trees methods

I-19 Asuka Suzuki Applying parametric bootstrap to generating a distribution of pseudo-objective function value difference for model selection in population pharmacokinetic analysis under time zone-specific nonexistence of observations

I-20 Veronika Voronova Exposure-safety analysis for oral GLP-1 analogues: the impact of between-occasion variability in drug absorption on nausea probability

I-21 Geraldine Celliere Simulation of first-in-human using an allometrically scaled population mechanistic TMDD model with preclinical monkey data, using the MonolixSuite

I-22 Emmanuelle Comets Additional features and graphs in the new npde library for R

I-23 Alexandre Duong External evaluation of population pharmacokinetic models of gentamicin in critically ill patients

I-24 Mehdi El Hassani Impact of sampling times on the predictive performance of tobramycin population pharmacokinetic models

I-25 Ibrahim El-Haffaf Simulation of the impact of unbound fraction variations on the predictive performance of a piperacillin-tazobactam population pharmacokinetic model.

I-26 Hanna Kunina Model Averaging Applied to Models With Various Biomarkers Using Multiple Weighting Methods

I-28 Fatemeh Aghai Physiologically-based pharmacokinetic modeling of ruxolitinib and posaconazole to predict the clinically relevant CYP3A4 mediated drug-drug interaction

I-29 Laura Ben Olivo Pharmacokinetic modeling based on physiology (PBPK): an innovative strategy for optimization of Piperacillin pharmacotherapy

I-30 Pavlos Chrysafidis A paradigm shift in oral drug absorption: The rise of physiologically based finite time pharmacokinetic (PBFTPK) models.

I-31 Rebekka Fendt Systematic evaluation of personalized physiologically based pharmacokinetic simulations

I-32 Angele Fleury A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol and caffeine

I-33 Bart Lammens A Physiologically Based Pharmacokinetic (PBPK) Model of Sildenafil to Predict Exposure in Pregnant Females. What is missing?

I-34 Jennifer Lang Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions

I-35 Antonina Nikitich Prediction of PD-L1 receptor occupancy in the tumor with PBPK/RO model of PD-L1 inhibitors

I-36 Luna Prieto Garcia Simvastatin disposition described by physiologically based pharmacokinetics: Does choice of applied PBPK platform matter?

I-37 Javier Reig-López Physiologically Based Pharmacokinetic Model for Atorvastatin: New Insights in Enzymatic and Transport Processes.

I-38 Mohammed Saleh Predicting the impact of healthy aging on the brain pharmacokinetic profiles using a translational modeling approach

I-39 Ayatallah Saleh Physiologically-based pharmacokinetic (PBPK) modelling to explore the pharmacokinetics (PK) and drug-drug interactions (DDI) potential of midazolam and 1-hydroxymidazolam: the hypothesis of lysosomal trapping

I-40 Christina Kovar Physiologically based pharmacokinetic (PBPK) modeling of (E)-clomiphene drug-drug-gene interactions with CYP2D6 and clarithromycin

I-41 Jennifer Tardiveau A Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline

I-42 Sung-yoon Yang Application of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine.

I-43 Emma Eckernäs Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine

I-44 Berfin Gülave Opioids distribution in human CNS might be altered due to pain-related increase of BBB permeability.

I-45 Heeyoon Jung Equivalent dose prediction of donepezil patch using population pharmacokinetic oral and patch combination model

I-46 Tatiana Karelina Quantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease

I-47 Orestis Papasouliotis Phase III dose selection for evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: exposure-response analyses from a phase II study in patients with multiple sclerosis

I-48 Satoshi Shoji Population Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies

I-49 Satoshi Shoji Prediction of Free Target Suppression Following Subcutaneous Administration of Tanezumab Based on Target-mediated Drug Disposition Approximation Model

I-50 Hanna Silber Baumann Population pharmacokinetic analysis of Satralizumab in NMOSD patients and healthy volunteers.

I-51 Jae Eun Ahn Model-Based Meta-Analysis of Triglyceride Reduction in Patients with Hypertriglyceridemia

I-52 Alessandro Boianelli Understanding the relationship between in vitro potency, nausea and clinical efficacious concentrations for GLP-1 receptor agonists

I-54 Kwan Cheol Pak PK and PD modeling and simulation of GX-H9 in the adult patients with growth hormone deficiency

I-55 Daniel Röshammar The population PKPD of unacylated and acylated ghrelin following single rising doses of BI 1356225 in healthy subjects is impacted by the time since last meal

I-56 Elrod Chris SAEM in Pumas – A systematic evaluation and benchmarking

I-57 Charles Margossian Solving ODEs in a Bayesian context: challenges and opportunities

I-58 Andreas Noack Generalized FOCE with Pumas

I-59 Monika Twarogowska Implementation of the standard concentration - QTc study using MonolixSuite applications on the example of Dofetilide.

I-60 Sergei Vavilov Parameter estimation in nonlinear fixed-effects QSP models: benchmark of optimization methods

I-61 Yi Zhang Torsten: Stan functions for pharmacometric applications - Improvements and new R interface workflow

I-62 Silvia Grandoni Therapeutic effect of anti-IL6 monoclonal antibodies in the treatment of COVID-19 in adults and multisystem inflammatory syndrome in children using siltuximab as a case study

I-63 Charlotte Kern Modeling changes in SARS-CoV-2 variants within-host transmissibility on antiviral drug effect

I-64 Timothy Knab A Physiologically-based Pharmacokinetic Modeling Approach to Support Candidate and First in Human Dose Selection for Bamlanivimab

I-65 Tarunendu Mapder Antiviral Treatment on SARS-Cov-2 Infected Epithelial Tissue Patch

I-66 Aurélien MARC Developing a model of SARS-CoV-2 viral dynamics under monoclonal antibody treatment.

I-67 Dirk Jan Moes Towards fixed dosing of tocilizumab in ICU admitted COVID-19 patients; results of an observational population pharmacokinetic and descriptive pharmacodynamic study

I-68 Venkatesh Pilla Reddy Application of modelling and simulation in development of an antibody cocktail for the prevention and treatment of COVID-19

I-69 Jingxian Chen Pharmacokinetics Optimization of Phase 2b/3 Study in Infants to Support the Development an RSV Monoclonal Antibody (MK-1654)

I-70 Romain Leroux New features in PFIM for optimal design in nonlinear mixed effects models using the S4 object system in R

I-71 Claude Magnard Simulx-GUI: a flexible, fast and user-friendly application for simulations

I-72 Yuanxi Zou A novel approach to evaluate the design of pediatric PK studies focused on accurate dose selection

I-73 Jiyeong Byeon Population PK-PD modeling and simulation of zolpidem to evaluate dosage regimen for sex effect in healthy Korean volunteers

I-74 Alejandra Schiavo A QSP model characterizing valproic acid -induced hyperammonemia and the impact of carnitine supplementation

I-75 Roberta Bartolucci Development of a genetic algorithm for covariate analysis in population pharmacokinetic models

I-76 Iasonas Kapralos Population pharmacokinetic modeling of the complex release kinetics of octreotide LAR: Defining sub-populations by cluster analysis

I-78 Ivan Borisov HetaProject – a Single Open Source Platform for Modeling, Simulation and Parameters Estimation in QSP

I-79 Jason Chittenden TADAH, a Shiny Application for Producing Report Ready Anti-Drug Antibody (ADA) Tables for MS Word

I-80 Ekaterina Mogilevskaya CYTOCON DB as storage of unified data on in vivo human concentrations of cells and molecules in health and disease

I-81 Rikard Nordgren Open source software from the Uppsala University Pharmacometrics group

I-82 Tarjinder Sahota NMproject new interface: end-to-end script-based NONMEM model development in RStudio